
Commentary|Videos|March 17, 2026
Treating Triple Negative Breast Cancer in the Frontline Setting
Author(s)Natalie Berger, MD
Fact checked by: Paige Britt
Frontline antibody-drug conjugates boost progression-free survival in metastatic triple-negative breast cancer, showing early overall survival gains and expanding options.
In an interview with Targeted Oncology, Natalie Berger, MD, hematologist and oncologist at the New York Presbyterian Medical Group, discusses some of the most exciting areas of breast cancer research, including treating triple negative breast cancer in the frontline setting.




























